

Agence de la santé

Public Health

Prevalence of antimicrobial-resistant organisms in smaller Canadian hospitals: Community, Rural, and Northern Acute Care Point Prevalence (CNAPP-19) Survey, 2019 – Supplemental material

Shari Thomas, Denise Gravel Tropper, Braden Knight, Donald Sheppard, Tanya Lary, Jami Mackenzie, Greg German, Charles Frenette, Kathryn Bush, Jennifer Ellison, Jennifer Happe, Jayson Shurgold

S1: Hospital survey questions

The 2019 Community, Rural, and Northern Acute Care Point Prevalence (CNAPP-19) Survey on Targeted Antimicrobial Resistant Organisms (ARO) and Antimicrobial Use (AMU)

Information to be collected as recorded 24 hours after the date/time of your hospital census, with lab follow-up at one week. Do not record personal identifiers.

			Agency of Canada publique du Canada
1.	Hospital code:		As assigned by PHAC, and must appear as the first three digits on all patient ID codes associated with this hospital.
2.	Census date (DD/MM/YYYY):		A date between February 1 and March 30, 2019.
3.	Total number of eligible beds at 8:00 AM on the date of	a. Number of occupied eligible beds: b. Number of unoccupied eligible beds: Total number of clicible beds:	The total number of occupied eligible beds should be the number of patient surveys completed by your facility. Please see the survey protocol for the definition of an eligible bed.
	your census:	c. Total number of eligible beds:	definition of an eligible bed.
4.	Services provided by hospital:	□ Adult care, medical □ Adult care, surgical □ Obstetrics/Gynecology □ Trauma → (specify level): □ Pediatric care □ Long-term care □ Rehabilitation □ Solid organ transplant □ Bone marrow transplant	 □ Malignant hematology □ Dialysis □ ICU, general □ ICU, cardiac □ ICU, neonatal → (specify level): □ ICU, pediatric □ Burn □ Oncology □ Other, specify:
5.	Targeted ARO screening: Screening refers to the testing of patients without the presence of symptoms.	a. At admission	b. During admission
	Methicillin-resistant Staphylococcus aureus	 □ All patients □ Only medical/surgical patients □ Only patients that meet a risk definition □ No screening at admission □ Other (specify): 	 □ Close contacts of new cases □ Periodic ward surveys □ Targeted units only □ None □ Other (specify):



S1: Hospital survey questions (continued)

	Vancomycin-resistant Enterococcus	 □ All patients □ Only medical/surgical patients □ Only patients that meet a risk definition □ No screening at admission □ Other (specify): 	□ Close contacts of new cases □ Periodic ward surveys □ Targeted units only □ None □ Other (specify):
	Extended-spectrum beta- lactamase producing organisms	 □ All patients □ Only medical/surgical patients □ Only patients that meet a risk definition □ No screening at admission □ Other (specify): 	□ Close contacts of new cases □ Periodic ward surveys □ Targeted units only □ None □ Other (specify):
	Carbapenemase-producing organisms	 □ All patients □ Only medical/surgical patients □ Only patients that meet a risk definition □ No screening at admission □ Other (specify): 	□ Close contacts of new cases □ Periodic ward surveys □ Targeted units only □ None □ Other (specify):
6.	If applicable, summarize your risk definition(s) for screening:		
7.	Is your hospital currently experiencing an outbreak?	□ No □ Yes, specify organism(s):	
8.	Does your facility have a pharmacist with a designated responsibility for antimicrobial stewardship on site at your facility?	□ No □ Yes, specify the workload in terms of full-ti	me equivalency (FTE):
9.	Does your facility perform regular audits for antimicrobial use?	□ No □ Yes, how often are the audits conducted:	
10.	Does your facility have a list of antimicrobial agents whose use is restricted at your facility?	□ No □ Yes, specify the restricted antimicrobials:	

S1: Hospital survey questions (continued)

11.	Does your facility have written infection prevention and control policies and procedures related to the containment of antimicrobial-resistant organisms?	□ No □ Yes →	If Yes, does your facility perform audits of compliance with the policies?	□ Yes □ No
12.	Does your facility participate in a hand hygiene program?	□ No □ Yes		

S2: Patient questionnaire

The 2019 Community, Rural, and Northern Acute Care Point Prevalence (CNAPP-19) Survey on Targeted Antimicrobial Resistant Organisms (ARO) and Antimicrobial Use (AMU)

Information to be collected as recorded 24 hours after the date/time of your hospital census, with lab follow-up at one week. Do not record personal identifiers.								
1.	Patient ID Code:	[] - [Hospital Code Patient (Code]	Public He Agency o	ealth of Canada	Agence de publique du	
2.	Age: []	□ Year(s) □ Day(s) □ Month(s) □ Year of Birth	3.	Sex Select one	□ Male □ Female	_ C	Other	
4.	Type of ward: Select one	□ Adult ICU □ Coronary Care (not ICU) □ ER (admitted, awaiting inpatient b □ Hematology/Oncology/Bone Marro □ Medical □ Mixed ICU/CCU □ Mixed Medical/Surgical □ Neonatal ICU (specify level): [ransplant	□ Pediatri □ Pediatri □ Solid ora □ Step do	c ICU c ICU gantransp wn unit (including or Burn	ng Case Roc lant gynecology	
5.	Precaution(s): Select all that apply	□ Contact □ Droplet □ Airborne □ Cohort □ Other (specify): □ None (skip to question 7)	6.	Reason for Precaution(s): Select all that apply	□ MRSA □ VRE □ CDI □ ESBL □ CPO □ Syndron	□ Ot	eventative her (specify)	:
7.	7. Did the patient have any of the following infection types?							
	Bloodstream infection	Type of bloodstream infection: Was this infection healthcare-associated Microbiologic confirmation of targeted A		□ Yes	tral line □ No	□ Seconda □ Unknow □ Unknow □ ESBL(s)	/n	□ None
		Specify organism(s) identified:						



S2: Patient questionnaire (continued)

		· ·						
			ealthcare-associated?	□ Yes	□ No	□ Unknow		
	Skin/soft tissue		g conducted on culture/specimen?		□ No	□ Unknow		
	infection		mation of targeted ARO:	□ MRSA	□ VRE	□ ESBL(s)	□ CPO(s)	□ None
		Specify organism(s)	identified:					
		Microbiologictestin	g conducted on culture/specimen?	□ Yes	□ No	□ Unknow	n	
	Surgical site	Presence of targeted	-	□ MRSA	□ VRE	□ ESBL(s)	□ CPO(s)	□ None
	infection	Specify organism(s)		- IVIII JA	VIL			INOTIC
		Specify or gamsim(s)	acritinea.					
			oley urinary catheter present?	□ Yes	□ No	□ Unknow		
	Hain a makan ak		ealthcare-associated?	□ Yes	□ No	□ Unknow		
	Urinary tract infection		g conducted on culture/specimen?	□ Yes	□ No	Unknow		
	mection		mation of targeted ARO:	□ MRSA	□ VRE	□ ESBL(s)	□ CPO(s)	□ None
		Specify organism(s)	identified:					
		Was a ventilator in p	lace?	□ Yes	□ No	□ Unknow	n	
			ealthcare-associated?	□ Yes	□ No	□ Unknow	n	
	Pneumonia	L	g conducted on culture/specimen?	□ Yes	□ No	□ Unknow	n	
			mation of targeted ARO:	□ MRSA	□ VRE	□ ESBL(s)	□ CPO(s)	□ None
		Specify organism(s)	identified:					
	C. difficile infection	Was this infection h	ealthcare-associated?	□ Yes	□ No	□ Unknow	n	
	None of the abo	ve						
8.	Was the patien	t prescribed any anti	microhial?					
		<u> </u>	s) prescribed (Specify up to 5, below)					
		□ No antimicrobial p	• •					
		·	(Ella of Sarvey)					
Ant	imicrobial 1:	Name: 						
		Route:		renteral		□ Inhala	tion	
	į		□ Rectal					
		Indication for use:	□ Empiric (without microbiolog	_		□ Proph	•	
	ļ		☐ Targeted (based on microbio	ologic resu	ults)	□ Unabl	e to deterr	nine
		Reason prescribed						
		(specify):				□ Unabl	e to deterr	nine
Ant	imicrobial 2:	Name:						
			□ Oral □ Pai	renteral		 □ Inhala	tion	
		Route:	□ Rectal					
			☐ Empiric (without microbiolog	gic results	s)	□ Proph	vlaxis	
		Indication for use:	□ Targeted (based on microbio	-	-	•	e to deterr	nine
		Reason prescribed						
		(specify):				□ Unabl	e to deterr	nine
Ant	imicrobial 3:	Name:						
	ŀ		□ Oral □ Pai	renteral		 □ Inhala	tion	
		Route:	□ Rectal	enterai			LIOII	
		Indication for use:	☐ Empiric (without microbiolog	gic results	s)	□ Proph	ylaxis	
		Indication for use:	☐ Targeted (based on microbid			•	e to deterr	nine
		Reason prescribed						



S2: Patient questionnaire (continued)

Antimicrobial 4:	Name:					
	Route:	□ Oral □ Rectal	□ Parenteral	□ Inhalation		
	Indication for use:		microbiologic results) on microbiologic results)	□ Prophylaxis□ Unable to determine		
	Reason prescribed (specify):	☐ Unable to determine				
Antimicrobial 5:	Name:					
	Route:	□ Oral □ Rectal	□ Parenteral	□ Inhalation		
	Indication for use:		microbiologic results) on microbiologic results)	□ Prophylaxis□ Unable to determine		
	Reason prescribed (specify):			☐ Unable to determine		
9. Notes:						